Literature DB >> 14636681

A virulence attenuated amoebapore-less mutant of Entamoeba histolytica and its interaction with host cells.

Shay Bujanover1, Uriel Katz, Rivka Bracha, David Mirelman.   

Abstract

Entamoeba histolytica, the protozoan parasite which causes amoebiasis, is an exclusively human pathogen so developing a vaccine could effectively impact the spread of the disease. Recently we developed a genetically modified avirulent strain, termed G3, from the virulent E. histolytica strain HM-1:IMSS. The new strain lacks the important virulence factor, the amoebapore-A. The objective of our current study was to investigate the avirulence of the attenuated strain as well as to examine the antigenic and immunogenic responses of these trophozoites as potential candidates for a live vaccine. Functional assays were conducted to characterise the virulent behaviour of the G3 strain. This behaviour was compared to the virulent strain HM-1:IMSS and the non-virulent strain Rahman. Western blots were conducted to confirm the lack of amoebapore-A in the E. histolytica G3 strain and to demonstrate that it had no influence on the presence of other virulence factors. Results of these two sets of tests proved the G3 strain to be phenotypically similar to the avirulent Rahman strain while antigenically identical to the virulent HM-1:IMSS, apart from the lack of the amoebapore-A protein. Intraperitoneal immunisation of hamsters with G3 trophozoites compared to sham immunised hamsters resulted in IgG anti-HM-1:IMSS antibodies. The level of humoral response was variable and further testing has to take place before introducing this new strain as a vaccine.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14636681     DOI: 10.1016/s0020-7519(03)00268-6

Source DB:  PubMed          Journal:  Int J Parasitol        ISSN: 0020-7519            Impact factor:   3.981


  14 in total

1.  Transcriptional gene silencing reveals two distinct groups of Entamoeba histolytica Gal/GalNAc-lectin light subunits.

Authors:  Rivka Bracha; Yael Nuchamowitz; Nomy Wender; David Mirelman
Journal:  Eukaryot Cell       Date:  2007-08-31

2.  Intestinal invasion by Entamoeba histolytica.

Authors:  Shahram Solaymani-Mohammadi; William A Petri
Journal:  Subcell Biochem       Date:  2008

Review 3.  A short guided tour through functional and structural features of saposin-like proteins.

Authors:  Heike Bruhn
Journal:  Biochem J       Date:  2005-07-15       Impact factor: 3.857

Review 4.  Tissue destruction and invasion by Entamoeba histolytica.

Authors:  Katherine S Ralston; William A Petri
Journal:  Trends Parasitol       Date:  2011-03-26

5.  Downregulation of an Entamoeba histolytica rhomboid protease reveals roles in regulating parasite adhesion and phagocytosis.

Authors:  Leigh A Baxt; Elena Rastew; Rivka Bracha; David Mirelman; Upinder Singh
Journal:  Eukaryot Cell       Date:  2010-06-25

6.  Entamoeba histolytica rhomboid protease 1 has a role in migration and motility as validated by two independent genetic approaches.

Authors:  Elena Rastew; Laura Morf; Upinder Singh
Journal:  Exp Parasitol       Date:  2015-04-15       Impact factor: 2.011

7.  Comparative genomic hybridizations of Entamoeba strains reveal unique genetic fingerprints that correlate with virulence.

Authors:  Preetam H Shah; Ryan C MacFarlane; Dhruva Bhattacharya; John C Matese; Janos Demeter; Suzanne E Stroup; Upinder Singh
Journal:  Eukaryot Cell       Date:  2005-03

8.  Identification of an Entamoeba histolytica serine-, threonine-, and isoleucine-rich protein with roles in adhesion and cytotoxicity.

Authors:  Ryan C MacFarlane; Upinder Singh
Journal:  Eukaryot Cell       Date:  2007-09-07

Review 9.  Host-Parasite interactions in Entamoeba histolytica and Entamoeba dispar: what have we learned from their genomes?

Authors:  I W Wilson; G D Weedall; N Hall
Journal:  Parasite Immunol       Date:  2012 Feb-Mar       Impact factor: 2.280

10.  Transcriptional silencing of multiple genes in trophozoites of Entamoeba histolytica.

Authors:  Rivka Bracha; Yael Nuchamowitz; Michael Anbar; David Mirelman
Journal:  PLoS Pathog       Date:  2006-05-26       Impact factor: 6.823

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.